ArticleCardiovascular diabetology2026
Association of the cholesterol, high-density lipoprotein, and glucose (CHG) index with mortality after acute myocardial infarction: evidence from two large prospective cohorts.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients with acute myocardial infarction (AMI) continue to face a considerable risk of death, even in the era of contemporary reperfusion and secondary prevention. Metabolic abnormalities may partly explain this residual risk. The cholesterol, high-density lipoprotein, and glucose (CHG) index, calculated as Ln{[total cholesterol (TC, mg/dL) × fasting blood glucose (FBG, mg/dL)]/[2 × high-density lipoprotein cholesterol (HDL-C, mg/dL)]}, is a recently proposed marker integrating lipid and glucose metabolism. We primarily aimed to examine the association between the CHG index and mortality in patients with AMI.
methodsWe analyzed two prospective cohorts, including 8,782 patients with AMI from the China Acute Myocardial Infarction (CAMI) registry and 3,466 AMI patients undergoing percutaneous coronary intervention at Fuwai Hospital. Outcomes included in-hospital, 1-year, and 2-year all-cause mortality in the CAMI cohort, and all-cause mortality in the Fuwai Hospital cohort. Associations between the CHG index and mortality were assessed using Cox proportional hazards models and restricted cubic splines. Discrimination, reclassification, and decision curve analyses were performed as secondary exploratory analyses.
resultsIn the CAMI cohort, higher CHG levels were associated with a graded increase in mortality risk. After multivariable adjustment, patients in the highest CHG tertile had higher risks of in-hospital mortality [hazard ratio (HR): 2.66, 95% confidence interval (CI): 1.63-4.32], 1-year mortality (HR: 2.44, 95% CI: 1.81-3.30), and 2-year mortality (HR: 2.41, 95% CI: 1.78-3.25) compared with those in the lowest tertile. Consistent findings were observed in the Fuwai Hospital cohort, in which the highest CHG tertile was associated with higher all-cause mortality after multivariable adjustment (HR: 2.16, 95% CI: 1.28-3.63). Restricted cubic spline analyses showed an approximately linear relationship between CHG and mortality. In secondary exploratory analyses, the CHG index yielded higher areas under the curve than the TyG index in both cohorts. In the CAMI cohort, adding CHG to the Global Registry of Acute Coronary Events (GRACE) score resulted in statistically significant but modest improvements in discrimination and reclassification and increased the net benefit in decision curve analysis.
conclusionsA higher CHG index was consistently associated with increased mortality risk after AMI across two independent cohorts, although its clinical utility requires further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.